«I am getting better» and «I feel good»: searching for an objective criterion for a clinical response to analgesic therapy for rheumatic diseases by A. E. Karateev, E. Yu. Pogozheva, V. N. Amirdzanova, E. S. Filatova, V. A. Nesterenko

“…The PARACELS study has shown that in Russian patients receiving analgesic therapy, MCII can correspond to a pain reduction of >30 mm on VAS (>40% of the baseline level), PASS can do to its reduction of >40 mm on VAS (>60% of the baseline level).…”
Get full text

CAN ACECLOFENAC BE CONSIDERED AS A MODERN SUCCESSOR OF THE «GOLD STANDARD» NSAID DYCLOFENAC? REVIEW OF RUSSIAN DATA by A. E. Karateev, E. Yu. Pogozheva, E. S. Filatova

Subjects: Get full text

Satisfaction with analgesic therapy in patients with rheumatic diseases in real clinical practice, according to the KOMPAS study (Quality of Pain Relief in the Opinion of Patients with Arthritis and Back Pain) by E. Yu. Pogozheva, A. E. Karateev, N. A. Bulgakova, V. N. Amirdzhanova, E. S. Filatova, V. A. Nesterenko, A. M. Lila

“…Educational work with patients and a personalized approach to prescribing analgesic therapy is needed.…”
Get full text

Is there an alternative to diclofenac i/m injections for rapid relief of severe pain? Results of randomized controlled and partially blind forsage study by A. E. Karateev, E. Yu. Pogozheva, E. S. Filatova, A. M. Lila, V. N. Amirdjanova, V. A. Nesterenko

“…DPS is not inferior to i/m Diclofenac injections in terms of analgesic potential and rapid onset of pain relief. …”
Get full text

The safety of nonsteroidal anti-inflammatory drugs in population-based studies: the benefits of aceclofenac by E. Yu. Pogozheva, A. E. Karateev, V. N. Amirdzhanova

“…Therefore, drugs with analgesic effects, primarily nonsteroidal anti-inflammatory drugs (NSAIDs), are among the most commonly used ones in the combination therapy of rheumatic diseases. …”
Get full text

A very early clinical response to treatment with the Janus kinase inhibitor tofacitinib in patients with active rheumatoid arthritis: the dynamics of pain and central sensitization... by A. E. Karateev, E. S. Filatova, E. Yu. Pogozheva, V. N. Amirdzhanova, E. L. Nasonov, A. M. Lila, V. I. Mazurov, A. Yu. De, A. A. Baranov, N. A. Lapkina, G. V. Lukina, N. A. Kiryukhina, S. Yu. Davidyan, T. S. Salnikova, R. R. Samigullina, D. S. Chakieva, I. M. Marusenko, O. V. Semagina, M. Yu. Semchenkova, A. F. Davydova, E. V. Kalinina

“…The use of the JK inhibitor TOFA can achieve a rapid analgesic effect, inter alia due to its effect on CS and NPC.…”
Get full text

Evaluation of the effectiveness of Tofacitinib in rheumatoid arthritis in real clinical practice: The relationship between pain relief in the first 4 weeks and disease activity aft... by A. E. Karateev, E. Yu. Pogozheva, V. N. Amirjanova, E. S. Filatova, A. M. Lila, V. I. Mazurov, R. R. Samigullina, A. M. Dadalova, A. Yu. Dyo, D. S. Chakieva, A. A. Baranov, N. A. Lapkina, E. N. Koltsova, N. A. Kiryukhina, I. N. Shchendrigin, T. G. Rasevich, A. F. Davydova, I. V. Semizarova, I. A. Shafieva, I. B. Bashkova, D. A. Bobrikova, D. A. Murtazalieva, I. N. Kushnir, E. V. Kalinina, T. S. Salnikova, I. M. Marusenko, O. V. Semagina, I. B. Vinogradova, D. G. Krechikova, M. Yu. Semchenkova, E. L. Nasonov

“…The use of the JAK inhibitor TOFA allows achieving a quick analgesic effect and reducing the signs of CS. An early clinical response to TOFA (pain relief) predicts a decrease in RA activity after 3 and 6 months of therapy.…”
Get full text

Evaluation of the efficacy of injectable chondroitin sulfate for knee osteoarthritis in real clinical practice by E. Yu. Pogozheva, A. E. Karateev

“…The advantages of this procedure are an enhanced bioavailability of SMDs, an accelerated onset of an analgesic effect, and higher patient adherence to therapy. …”
Get full text

Regular use of non-steroidal anti-inflammatory drugs can effectively control pain and global health in patients with moderate activity of rheumatoid arthritis by A. E. Karateev, E. Yu. Pogozheva, V. N. Amirdzhanova, E. S. Filatova, V. A. Nesterenko

“…Aceclofenac is not inferior to other NSAIDs in analgesic potential and exceeds them in tolerability.…”
Get full text

An old friend: 25 years of meloxicam use in Russia. by A. E. Karateev, E. L. Nasonov, E. Yu. Pogozheva, E. S. Filatova, V. N. Amirdzhanova, V. A. Nesterenko

“…In our country, this drug has become one of the most popular analgesics. Until now, the original meloxicam has enjoyed a high level of trust among Russian doctors and patients. …”
Get full text